TABLE 1

Mean Values and Respective SD of SUVmax Among Different Groups of Patients

				Effect (%)^*
Parameter	Patients (n)	Mean SUVmax ± SD	P	Estimate	95% CI
Site
Pancreas	23	59.4 ± 48.6	0.006^†	200.2	123.1–325.8
			0.003^‡	303.8	149.5–617.4
Gastrointestinal tract	18	26.5 ± 18.6	0.255^‡	151.7	73.2–314.6
Lung	6	20.4 ± 13.5
Syndrome
Yes	16	54.5 ± 56.3	0.214	139.5	82.0–237.2
No	31	35.3 ± 26.7
MEN 1 syndrome
Yes	6	61.6 ± 56.3	0.370	140.7	65.8–301.1
No	41	39.0 ± 32.1
Stage
I–II	4	22.5 ± 4.4	0.628^§	132.1	41.8–417.7
			0.395^‖	68.1	27.6–167.7
III	5	18.1 ± 7.5	0.109^‖	51.5	22.8–116.5
IV	38	47.0 ± 42.6
World Health Organization classification
Well-differentiated	42	44.1 ± 41.0	0.036	233.6	106.0–514.9
Poorly differentiated	5	23.1 ± 22.1
Ki67
≤5	20	47.0 ± 48.7	0.842	94.0	50.1–176.2
>5	13	47.0 ± 36.1
SSTR2A score
High	6	96.7 ± 72.4	0.037	331.4	108.7–1010.4
Low	8	31.5 ± 27.7
Follow-up
Stable disease/PR	25	55.6 ± 47.6	0.001	226.0	140.1–364.5
PD	19	23.9 ± 16.6

↵* ANOVA was applied on log-transformed data. Effects were estimated as antilog transformation of analyzed data and are expressed as percentages.
↵† P values vs. gastrointestinal tumors.
↵‡ P values vs. lung tumors.
↵§ P values vs. stage III.
↵‖ P values vs. stage IV.
MEN 1 = multiple endocrine neoplasia type 1.
Comparisons among groups were made using 1-way ANOVA.